Tinnitus - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Tinnitus - Pipeline Review, H1 2016', provides an overview of the Tinnitus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Tinnitus - The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects - The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Tinnitus Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Tinnitus - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tinnitus Overview 7 Therapeutics Development 8 Pipeline Products for Tinnitus - Overview 8 Pipeline Products for Tinnitus - Comparative Analysis 9 Tinnitus - Therapeutics under Development by Companies 10 Tinnitus - Therapeutics under Investigation by Universities/Institutes 11 Tinnitus - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Tinnitus - Products under Development by Companies 16 Tinnitus - Products under Investigation by Universities/Institutes 17 Tinnitus - Companies Involved in Therapeutics Development 18 AudioCure Pharma GmbH 18 Auris Medical Holding AG 19 Flexion Therapeutics, Inc. 20 Knopp Biosciences LLC 21 Merz Pharma GmbH & Co. KgaA 22 Otonomy, Inc. 23 SciFluor Life Sciences, LLC 24 Sound Pharmaceuticals, Inc. 25 Tinnitus - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 34 acamprosate calcium - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 AM-102 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AUT-3 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Drug to Activate KCNQ for Tinnitus - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 esketamine hydrochloride - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 gacyclidine SR - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 neramexane mesylate - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SF-0034 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules for Tinnitus - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 SPI-1005 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SPI-3005 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Tinnitus - Recent Pipeline Updates 52 Tinnitus - Dormant Projects 58 Tinnitus - Product Development Milestones 59 Featured News & Press Releases 59 Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311 59 Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311 59 Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio 59 Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience 60 Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals 60 Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus 61 Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City 62 Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101 62 Feb 11, 2015: Auris Medical Announces Recently Granted Patent in China for the Treatment of Tinnitus 63 Jan 14, 2015: Auris Medical Holding AG Achieves 50% Enrolment Milestone in Post-Acute Tinnitus Stratum of TACTT3 Clinical Trial 63 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for Tinnitus, H1 2016 8 Number of Products under Development for Tinnitus - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Comparative Analysis by Unknown Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Tinnitus - Pipeline by AudioCure Pharma GmbH, H1 2016 18 Tinnitus - Pipeline by Auris Medical Holding AG, H1 2016 19 Tinnitus - Pipeline by Flexion Therapeutics, Inc., H1 2016 20 Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2016 21 Tinnitus - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 22 Tinnitus - Pipeline by Otonomy, Inc., H1 2016 23 Tinnitus - Pipeline by SciFluor Life Sciences, LLC, H1 2016 24 Tinnitus - Pipeline by Sound Pharmaceuticals, Inc., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 33 Tinnitus Therapeutics - Recent Pipeline Updates, H1 2016 52 Tinnitus - Dormant Projects, H1 2016 58
List of Figures
Number of Products under Development for Tinnitus, H1 2016 8 Number of Products under Development for Tinnitus - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Top 10 Targets, H1 2016 27 Number of Products by Stage and Top 10 Targets, H1 2016 27 Number of Products by Top 10 Mechanism of Actions, H1 2016 29 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Stage and Top 10 Molecule Types, H1 2016 33
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.